Swati Naik – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:44 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Swati Naik – VJRegenMed https://mirror.vjregenmed.com 32 32 Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML https://mirror.vjregenmed.com/video/wsoxj21v9q0-preliminary-results-from-phase-i-study-of-cd123-car-t-therapy-in-pediatric-rr-aml/ Thu, 09 Mar 2023 11:31:44 +0000 https://mirror.vjregenmed.com/video/wsoxj21v9q0-preliminary-results-from-phase-i-study-of-cd123-car-t-therapy-in-pediatric-rr-aml/ In this video, Swati Naik, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, discusses the rationale and preliminary results from a Phase I study evaluating the safety and feasibility of CD123-targeting CAR-Ts in pediatric patients with relapsed/refractory (R/R) acute myeloid leukemia (AML; NCT04318678). Dr Naik first explains the challenges associated with designing effective CAR-Ts for AML, including the identification of a suitable target, patient heterogeneity, and the aggressive and immunosuppressive nature of the disease. Dr Naik then comments on the results of the study, which showed evidence of expansion and anti-leukemic activity at different dose levels, with no dose-limiting toxicities. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>